Asciminib May Be an “Attractive” Option in Newly Diagnosed CML Populations
Published: | Updated:
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Articles by Timothy P. Hughes, MD, FRACP, FRCPA, MBBS, FAAHMS
Advertisement
Latest Updated Articles
Asciminib May Be an “Attractive” Option in Newly Diagnosed CML PopulationsPublished: June 1st 2024 | Updated: June 3rd 2024
Advertisement
Advertisement
Trending on CancerNetwork
1
Will The FDA Approve Iberdomide in Relapsed/Refractory Multiple Myeloma?
2
FDA Grants Tentative Approval to PNT2003 for GEP-NETs
3
FDA Grants Pre-Market Approval to AI Device for Breast Cancer Surgery
4
DURGA-1 Trial Shows Encouraging Results With Novel Multiple Myeloma Agent
5